Cell-Based Drug Discovery
Creation of cells expressing disease genes for use to identity and develop new prospective drug candidates for clinical trials. We already have the human genome - Chromovert® has the demonstrated potential to action that data to make a drug for every gene.
Personalized Medicine
Making a drug for just one person or only one family was never more possible than now. Together with human genome data worldwide, our one-off drug discovery efforts add up to provide a growing arsenal of drugs for all of humankind.
Biologics & Vaccine Manufacturing
Creation of cell factories to produce protein, antibody and peptide drugs, along with creation of cells to produce immunogens to induce defensive vaccine responses and agents for gene therapy.
Biodefense and Pandemic Resiliency
Biodefense & Security: when speed counts, Chromovert® Technology saves time for vaccine and biologics production for accelerated biologics testing and production.
Cell & Stem Cell Therapies
Engineering of cells and stem cells to cure and treat disease. Now that we have the human genome, let's make a drug for every gene.
© 2024
Secondcell Bio
© 2024
Secondcell Bio
© 2024
Secondcell Bio
© 2024
Secondcell Bio
If you had to guess the target of a certain drug, your best odds are with “G-Protein Coupled Receptors (GPCRs)”. Drugs targeting members of this integral membrane protein superfamily, which transmit chemical signals into a wide array of different cell types, represent the core of modern medicine.
GPCRs account for the majority of best-selling drugs and about 50% of all prescription pharmaceuticals on the market. There is broad consensus that GPCRs will remain at the hub of drug development for the foreseeable future.
Today we start with GPCRs, tomorrow we find medicines for every disease gene in the Human Genome. Chromovert® Technology has been shown to improve and automate the drug discovery process. Next up, Drug Discovery at Scale.
of prescribed medicines target a member of the GPCR receptor family
© 2024
Chromovert® Technology
GPCRs are prominent components of all pharmaceutical and consumer pipelines, and many drug discovery firms focus exclusively on these receptors.
The path to novel GPCR-targeted medicines is not routine. Most GPCR-modulating drugs on the market weren't initially targeted to a specific protein, but were developed on the basis of functional activity observed in an assay. That they activated or inhibited a GPCR specifically was only later discovered.
Post-Human Genome Project, however, GPCR targets are the starting points for most drug discovery endeavors. And there is still much to be learned about how GPCRs work and how they can be selectively modulated. Fortuitously, technologies designed specifically to tackle the GPCR challenge are blossoming.
What they said about us?
The Scientist
https://www.the-scientist.com
Chromovert® has been demonstrated to access dozens of previously out-of-reach GPCRs in their native and physiologically-relevant form (including heterodimeric GPCRs).